PDF(Pubmed)
Abstract：
The global public health nonprofit organization PATH hosted the third Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Washington, DC, from November 29 to December 1, 2022. This international gathering focused on cutting-edge research related to the development of vaccines against neglected diarrheal pathogens including Shigella, enterotoxigenic Escherichia coli (ETEC), Campylobacter, and non-typhoidal Salmonella. In addition to the conference\'s plenary content, the agenda featured ten breakout workshops on topics of importance to the enteric vaccine field. This unique aspect of VASE Conferences allows focused groups of attendees to engage in in-depth discussions on subjects of interest to the enteric vaccine development community. In 2022, the workshops covered a range of topics. Two focused on the public health value of enteric vaccines, with one examining how to translate evidence into policy and the other on the value proposition of potential combination vaccines against bacterial enteric pathogens. Two more workshops explored new tools for the development and evaluation of vaccines, with the first on integrating antigen/antibody technologies for mucosal vaccine and immunoprophylactic development, and the second on adjuvants specifically for Shigella vaccines for children in low- and middle-income countries. Another pair of workshops covered the status of vaccines against two emerging enteric pathogens, Campylobacter and invasive non-typhoidal Salmonella. The remaining four workshops examined the assessment of vaccine impact on acute and long-term morbidity. These included discussions on the nature and severity of intestinal inflammation; cellular immunity and immunological memory in ETEC and Shigella infections; clinical and microbiologic endpoints for Shigella vaccine efficacy studies in children; and intricacies of protective immunity to enteric pathogens. This article provides a brief summary of the presentations and discussions at each workshop in order to share these sessions with the broader enteric vaccine field.
摘要：
全球公共卫生非营利组织PATH在华盛顿主办了第三届志贺氏菌和肠毒素大肠杆菌疫苗会议，DC,2022年11月29日至12月1日。这次国际会议的重点是与开发针对包括志贺氏菌在内的被忽视的腹泻病原体的疫苗有关的前沿研究，产肠毒素大肠杆菌（ETEC），弯曲杆菌,和非伤寒沙门氏菌.除了会议的全体会议内容，议程包括十个关于肠疫苗领域重要主题的分组研讨会。VASE会议的这一独特方面允许重点与会者群体就肠溶疫苗开发社区感兴趣的主题进行深入讨论。2022年，研讨会涵盖了一系列主题。两个重点是肠溶疫苗的公共卫生价值，一个研究如何将证据转化为政策，另一个研究针对细菌性肠道病原体的潜在组合疫苗的价值主张。另外两个讲习班探讨了开发和评估疫苗的新工具，第一个关于整合抗原/抗体技术用于粘膜疫苗和免疫预防的发展，第二个是针对低收入和中等收入国家儿童的志贺氏菌疫苗的佐剂。另一对讲习班涵盖了针对两种新出现的肠道病原体的疫苗状况，弯曲杆菌和侵袭性非伤寒沙门氏菌。其余四个讲习班审查了疫苗对急性和长期发病率影响的评估。其中包括有关肠道炎症的性质和严重程度的讨论；ETEC和志贺氏菌感染中的细胞免疫和免疫记忆；儿童志贺氏菌疫苗功效研究的临床和微生物学终点；以及对肠道病原体的保护性免疫的复杂性。本文简要总结了每个研讨会上的演讲和讨论，以便与更广泛的肠疫苗领域分享这些会议。
